Mayo Clinic representatives Brian Netzel, Stefan Grebe, M.D., Ph.D., and Alicia Algeciras-Schimnich, Ph.D. authored the article, “Usefulness of a Thyroglobulin Liquid Chromatography–Tandem Mass Spectrometry Assay for Evaluation of Suspected Heterophile Interference,” in the July issue of Clinical Chemistry to describe their study which determined whether Tg measurement by LC-MS/MS would allow accurate quantification in samples with suspected HAB interference.
As of Aug. 22, there have been over 2600 suspected or confirmed cases of Ebola hemorrhagic fever. Of these cases, two adult United States nationals were admitted to Emory University Hospital in Atlanta, GA during the first week of August 2014 for treatment. To discuss their treatment, doctors of Emory Hospital authored the article, “Laboratory Test Support for Ebola Patients Within a High-Containment Facility,” in American Society for Clinical Pathology’s Lab Medicine Journal.
A recent article in The New York Times reported on celiac disease, an autoimmune disorder of the gut triggered by the gluten proteins in wheat and other grains, and its connection to the human brain. Upon analysis of several cases, treating an autoimmune disease of the gut (by avoiding gluten) resolved what looked like a debilitating disorder of the brain.
In the September issue of the American Journal of Clinical Pathology, Mayo Clinic’s Saba Yasir, MBBS, Daniel Visscher, M.D., Sarah Jenkins, MS, and Aziza Nassar, M.D., conducted a study to evaluate histologic features that can help distinguish phyllodes tumor (PT) from cellular fibroadenoma (CFA) on core needle biopsy (CNB) specimens.
European Hospital highlighted Mayo Clinic’s Piero Rinaldo, M.D., Ph.D., for his discussion on how big data can help to avoid false positives in newborn screening, which he presented at the 2014 AACC Annual Meeting & Clinical Lab Expo in July.
The Dark Daily discusses why highlighting the contribution of pathology to the practice of medicine is an effective way to educate consumers, and learn about the history of certain developments, including the frozen sections technique which was pioneered at Mayo Clinic.
Recent research from the Mayo Clinic found four different assays for the detection of norovirus in stool specimens performed comparably. Researchers tested a laboratory-developed real-time polymerase chain reaction and three commercial molecular assays.
Utilizing the “frozen sections” technique, Mayo Clinic surgical and laboratory teams work together to provide patients immediate treatment by analyzing patients’ tissue samples while they are still laying on the operating table under anesthesia. In addition to helping patients, this technique cuts cost by eliminating the need for follow-up surgery when analysis finds not all the cancerous tissue has been removed.
On Monday, August 11, the Food and Drug Administration announced its approval of the first stool-based colorectal screening test co-developed by Exact Sciences and Mayo Clinic. Exact Sciences will be the sole provider of this new test. While the test is based on Mayo Clinic research, the test will not be available through Mayo Medical Laboratories.
The July article, “Tackling Reagent Lot-to-Lot Verification,” in Clinical Laboratory News, written by Alicia Algeciras-Schimnich, Ph.D., associate professor of Mayo Clinic Laboratory Medicine and Pathology and director of Mayo’s Clinical Immunoassay Laboratory, discusses the importance of reagent lot performance verification.
Eric Wieben, Ph.D., director of Mayo’s Medical Genome Facility in Rochester, Minn., discusses how Mayo Clinic is managing big data from personalized medicine in the June issue of CAP TODAY.
In the May/June issue of Medical Lab Management, Jane Hermansen, MBA, MT(ASCP), network manager for Mayo Medical Laboratories, discusses using quality assurance (QA) in the laboratory.
When standard molecular techniques fail in identifying rare and unusual tumor genetic variants, success is now being found through the use of next-generation sequencing (NGS).